Case Studies Pfizer Builds on the Genedata Biopharma E2E Workflow Platform

Edit This Case Study Record

	Pfizer Builds on the Genedata Biopharma E2E Workflow Platform

Pfizer Builds on the Genedata Biopharma E2E Workflow Platform

Technology Category	Analytics & Modeling - Machine Learning Platform as a Service (PaaS) - Data Management Platforms
Applicable Industries	Healthcare & Hospitals Pharmaceuticals
Applicable Functions	Product Research & Development Quality Assurance
Use Cases	Predictive Quality Analytics
Services	Data Science Services System Integration
Challenge	Pfizer, a global biopharma giant, faced the challenge of aligning workflows and centralizing data for more than 200 scientists located at 6 sites around the world. The company's diverse and growing biopharma R&D operations required a central system to share data and align large-molecule R&D processes. With R&D teams spread across the globe, vast amounts of data were being collected in silos, making it difficult for teams to share information. This impeded collaboration and led to process inefficiencies. After an aborted attempt with a develop-as-you-go approach, Pfizer decided to evaluate the market in search of a commercial enterprise data management system for their large-molecule R&D groups. The desired system would need to act as a backbone platform and central repository for Pfizer’s biological R&D workflows and include tools able to capture specific instrumental data, workflows, analyses, and each group’s unique contribution to the overall biological drug discovery process at Pfizer. Read More
About Customer	Pfizer is the world’s largest pharmaceutical company, a research-based organization with significant R&D investment. The company's key research areas include inflammation and immunology, internal medicine, oncology, rare disease, and vaccines. Biotherapeutic discovery and development within Pfizer is centralized in the Biomedicine Design and Biotherapeutic PharmSci departments. With R&D teams spread across the globe, Pfizer delivers biotherapeutic treatments that benefit patients worldwide. The company has been a Genedata customer since 2015. Read More
Solution	After conducting a thorough market evaluation to identify an off-the-shelf enterprise system for large-molecule discovery, Pfizer decided to implement Genedata Biologics as their central repository for their biologics discovery data, including screening, molecular biology, engineering, expression, purification, and analytics. The platform works out of the box and includes unique and comprehensive built-in business logic for all major discovery technologies, such as phage and yeast display, hybridoma, or B-cell-based approaches, Pfizer was able to get up and running quickly. In addition, the platform’s open architecture made it possible for Pfizer to integrate it into their existing R&D and IT environment and to develop highly integrated custom tools on top. Three years after the deployment of Genedata Biologics, Pfizer decided to expand beyond discovery and implemented Genedata Bioprocess to support their large-molecule pharmaceutical development. Read More Log in to view content
Contents

Technology Category

Analytics & Modeling - Machine Learning

Platform as a Service (PaaS) - Data Management Platforms

Applicable Industries

Healthcare & Hospitals

Pharmaceuticals

Applicable Functions

Product Research & Development

Quality Assurance

Use Cases

Predictive Quality Analytics

Services

Data Science Services

System Integration

Challenge

Pfizer, a global biopharma giant, faced the challenge of aligning workflows and centralizing data for more than 200 scientists located at 6 sites around the world. The company's diverse and growing biopharma R&D operations required a central system to share data and align large-molecule R&D processes. With R&D teams spread across the globe, vast amounts of data were being collected in silos, making it difficult for teams to share information. This impeded collaboration and led to process inefficiencies. After an aborted attempt with a develop-as-you-go approach, Pfizer decided to evaluate the market in search of a commercial enterprise data management system for their large-molecule R&D groups. The desired system would need to act as a backbone platform and central repository for Pfizer’s biological R&D workflows and include tools able to capture specific instrumental data, workflows, analyses, and each group’s unique contribution to the overall biological drug discovery process at Pfizer.

About Customer

Pfizer is the world’s largest pharmaceutical company, a research-based organization with significant R&D investment. The company's key research areas include inflammation and immunology, internal medicine, oncology, rare disease, and vaccines. Biotherapeutic discovery and development within Pfizer is centralized in the Biomedicine Design and Biotherapeutic PharmSci departments. With R&D teams spread across the globe, Pfizer delivers biotherapeutic treatments that benefit patients worldwide. The company has been a Genedata customer since 2015.

Solution

After conducting a thorough market evaluation to identify an off-the-shelf enterprise system for large-molecule discovery, Pfizer decided to implement Genedata Biologics as their central repository for their biologics discovery data, including screening, molecular biology, engineering, expression, purification, and analytics. The platform works out of the box and includes unique and comprehensive built-in business logic for all major discovery technologies, such as phage and yeast display, hybridoma, or B-cell-based approaches, Pfizer was able to get up and running quickly. In addition, the platform’s open architecture made it possible for Pfizer to integrate it into their existing R&D and IT environment and to develop highly integrated custom tools on top. Three years after the deployment of Genedata Biologics, Pfizer decided to expand beyond discovery and implemented Genedata Bioprocess to support their large-molecule pharmaceutical development.

Impact #1	As a commercial off-the-shelf (COTS) product, Genedata Biologics went into operation for the first R&D user groups in just a few weeks, followed by adoption across the entire Pfizer Biomedicine Design discovery organization.
Impact #2	The system is now used by more than 250 people in 15 groups located at 6 Pfizer R&D sites around the globe and supports 200+ distinct discovery projects, including more than 900,000 clones, 28,000 lead molecules, 900 cell lines, and tens of thousands of protein batches and their respective analytics and QC results.
Impact #3	The system has helped to improve quality of results by eliminating errors resulting from passing spreadsheets and other ad hoc data exchange.

Impact #1

As a commercial off-the-shelf (COTS) product, Genedata Biologics went into operation for the first R&D user groups in just a few weeks, followed by adoption across the entire Pfizer Biomedicine Design discovery organization.

Impact #2

The system is now used by more than 250 people in 15 groups located at 6 Pfizer R&D sites around the globe and supports 200+ distinct discovery projects, including more than 900,000 clones, 28,000 lead molecules, 900 cell lines, and tens of thousands of protein batches and their respective analytics and QC results.

Impact #3

The system has helped to improve quality of results by eliminating errors resulting from passing spreadsheets and other ad hoc data exchange.

Benefit #1	Pfizer reported an increase, by a factor of as much as 10, in antibodies converted to full IgG per project.

Benefit #1

Pfizer reported an increase, by a factor of as much as 10, in antibodies converted to full IgG per project.

Download PDF Version

Overview

Pfizer Builds on the Genedata Biopharma E2E Workflow Platform

Operational Impact

Quantitative Benefit